ESMO 2025 movers – FDA volte-face to the rescue
Redemption of sorts comes for IO Biotech, but there’s no respite for Summit.
ESMO 2025 – bemarituzumab fails to convince
Amgen and Zai Lab’s FGFR2b antibody shows no benefit at the two-year mark.
ESMO 2025 – Incyte impresses in KRAS G12D
Response rates with INCB161734 in pancreatic cancer look in line with Revolution.
ESMO 2025 – more ivonescimab shots on goal for Summit
Harmoni-6 succeeds in first-line lung cancer, but the focus is on changes to Harmoni-3.
ESMO 2025 – little solace for Roche’s doomed TIGIT
A quartet of failed tiragolumab trials featured at ESMO over the weekend.
ESMO 2025 – no starring role for Exelixis’s Cabometyx follow-on
The Stellar-303 trial of zanzalintinib hits, but the discussant asks for more data and flags toxicity.
ESMO 2025 – J&J brings a new Rybrevant use into the fold
After promising early data in head and neck, J&J plans a new phase 3, Origami-5.
ESMO 2025 – Tubulis keeps the NaPi2b dream alive
The first TUB-040 data come just after Tubulis raised €308m.
ESMO 2025 – Novartis looks for Pluvicto prostate Addition
But the ESMO discussant recommends against widespread use in hormone-sensitive disease.
